The introduction of Retatrutide in the UK is sparking significant anticipation within the obesity community. This innovative dual agonist – targeting both GLP-1 and GIP – offers a significantly new approach to tackling weight challenges. Until recently, options have been limited for many, and Retatrutide embodies a promising prospect for indivi